Platinum-Cured Tubing: A Leap in Medical Device Safety and Market Speed

DONGGUAN, China – June 16, 2026 – In the high-stakes world of medical device manufacturing, the simplest components often carry the most risk. For decades, a hidden liability has existed within the flexible silicone tubing that serves as the lifeblood of systems for cardiac support, hemodialysis, and drug infusion. Now, a Dongguan-based manufacturer, Ruixiang Silicone, has released a new line of medical-grade tubing that directly addresses this fundamental material challenge, representing a significant step forward in both patient safety and operational efficiency for the industry.

The company’s launch of its platinum-cured silicone tubing series is more than just a product release; it's a systems-based solution to the persistent problems of material purity and manufacturing precision. By tackling issues at the chemical level and coupling them with a robust regulatory package, Ruixiang is offering device makers not just a component, but a strategic advantage in a market where time and trust are paramount.

The Chemistry of Purity

For years, the industry standard for many silicone applications has been peroxide curing. While effective at creating a durable, crosslinked silicone matrix, the process comes with a significant drawback: the decomposition of peroxide initiators generates residual byproducts. These small-molecule contaminants, including organic acids and ketones, become trapped within the material. If not completely removed through an intensive, high-temperature post-curing cycle, they can gradually leach out.

In a medical context, this leaching is a critical failure point. When tubing is used to transfer drug solutions or blood, these leached byproducts can contaminate the fluid, potentially altering its pH, degrading active pharmaceutical ingredients, or introducing toxins. Over time, the same residuals cause the tell-tale yellowing and surface blooming that signals material degradation. “For any application involving drug contact, peroxide-cured materials introduce an unacceptable level of risk and regulatory scrutiny,” commented one material scientist familiar with biocompatibility testing.

Ruixiang Silicone’s new product line sidesteps this problem entirely by employing a platinum-catalyzed addition cure process. This advanced chemistry is fundamentally cleaner. It works by directly combining vinyl and hydride siloxane groups to form new, stable carbon-silicon bonds without releasing any byproducts. The reaction is clean and complete. Because no residuals are created, the need for a high-temperature post-cure cycle to bake them out is eliminated. The practical result is a material of exceptional purity that remains colorless, transparent, and stable through extended storage and repeated autoclave sterilization cycles, allowing for crucial visual inspection of fluid lines during use.

Precision Engineering for Critical Flow

Beyond chemical purity, the physical integrity of medical tubing is non-negotiable, especially in applications demanding precise fluid delivery. In peristaltic pumps, which are common in infusion and dialysis systems, the pump rollers compress the tubing to propel fluid forward. Any inconsistency in the tube’s wall thickness translates directly into flow rate errors. Over thousands of hours of operation, these small deviations can accumulate, compromising therapeutic accuracy.

To address this, Ruixiang Silicone has engineered its manufacturing process around a core principle of consistency. The company utilizes a vertical extrusion process, where gravity assists the material flow, ensuring a remarkably uniform wall distribution across the tube’s cross-section. This method minimizes the risk of air entrapment and impurities, resulting in a bubble-free structure with exceptional dimensional stability. The company holds its inner and outer diameter tolerances to an impressive ±0.02 mm.

This level of precision enables the manufacturing of tubing for the next generation of miniaturized medical devices. With a minimum processable inner diameter of 0.14 mm and a wall thickness floor of 0.1 mm, the product line is suitable for micro-catheter assemblies and other precision infusion technologies where every micron matters. This entire process is conducted within a 5,000 m² facility housing GMP-compliant cleanrooms rated at ISO Class 8 (also known as Class 100,000), a standard that strictly limits airborne particulates to ensure the component’s cleanliness from the moment of its creation.

De-Risking the Supply Chain

For medical device companies, bringing a new product to market is a marathon of design, testing, and regulatory navigation. One of the most time-consuming and costly hurdles is material qualification. Every component that comes into contact with a patient or a therapeutic fluid must be rigorously proven to be safe and biocompatible, a process that can take months or even years.

This is where Ruixiang Silicone’s strategy becomes clear. The company has essentially front-loaded the compliance work. The new tubing series arrives with a comprehensive portfolio of the most critical certifications required for global market access:

• USP Class VI: The highest and most stringent classification from the United States Pharmacopeia, involving in vivo testing to ensure the material is non-toxic and causes no adverse biological reactions. It is a key requirement for market entry in North America.
• ISO 10993: The international standard for the biological evaluation of medical devices, providing the primary biocompatibility framework required for the European market.
• ISO 13485:2016: The globally recognized quality management system (QMS) standard for medical device manufacturing, which the U.S. FDA has recently adopted as its foundational QMS framework, signaling a move toward global harmonization.
• FDA-Registered Facility: Registration of the manufacturing site with the U.S. Food and Drug Administration, a prerequisite for selling into the American market.

As CEO Feng Zhen Huang stated, “Cardiac assist and hemodialysis procurement teams run long qualification cycles. The biocompatibility and extraction data they require takes time to generate regardless of who the supplier is. We completed that process on the platinum-cure line so customers entering those device categories are working with material that already carries the documentation.”

This pre-certified approach effectively de-risks the supply chain. It provides procurement and R&D teams with a component that is not just a piece of plastic, but a fully documented, regulatory-ready solution, drastically reducing the time and expense of internal validation and accelerating the path to commercialization.

A Shift in the Global Value Chain

Ruixiang Silicone’s launch is also indicative of a broader and more profound shift in the global manufacturing landscape. For decades, China has been seen as the world’s factory for low-cost, high-volume goods. This product, however, represents a clear move up the value chain into high-spec, mission-critical components that compete on quality, technology, and regulatory sophistication.

While established Western giants like Freudenberg Medical, Trelleborg, and Saint-Gobain have long dominated the high-performance medical materials market, this launch demonstrates that advanced manufacturing capabilities and stringent quality control are no longer their exclusive domain. With a reported 5,000 enterprise clients across more than 50 countries, Ruixiang is building a case that manufacturers in China can and will meet the world’s most demanding standards. This development promises to introduce greater competition and resilience into a supply chain that is critical for healthcare innovation worldwide. For leaders in the medical device sector, it signals an expanding field of potential strategic partners who can deliver not just parts, but a pathway to market.